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Rett syndrome (RTT) is a rare neurodevelopmental disorder usually caused by mutations in the X-linked genemethyl-CpG-binding
protein 2 (MECP2). SeveralMecp2mutant mouse lines have been developed recapitulating part of the clinical features. In particular,
Mecp2-308 female heterozygous mice, bearing a truncating mutation, are a validated model of the disease. While recent data suggest
a role for inflammation in RTT, little information on the inflammatory status in murine models of the disease is available. Here, we
investigated the inflammatory status by proteomic 2-DE/MALDI-ToF/ToF analyses in symptomaticMecp2-308 female mice. Ten
differentially expressed proteins were evidenced in theMecp2-308 mutated plasma proteome. In particular, 5 positive acute-phase
response (APR) proteins increased (i.e., kininogen-1, alpha-fetoprotein, mannose-binding protein C, alpha-1-antitrypsin, and
alpha-2-macroglobulin), and 3 negative APR reactants were decreased (i.e., serotransferrin, albumin, and apolipoprotein A1).
CD5 antigen-like and vitamin D-binding protein, two proteins strictly related to inflammation, were also changed. These results
indicate for the first time a persistent unresolved inflammation of unknown origin in the Mecp2-308 mouse model.
1. Introduction
Rett syndrome (RTT,MIM 312750) is a progressive neurode-
velopmental disorder, affecting almost exclusively the female
gender. With a frequency of approximately 1 : 10,000 live
births, it is a leading cause of severe intellectual disability
and autistic features in females [1, 2]. The classical clinical
picture of the disease [3] is characterized by a period of 6 to
18 months of apparently normal neurodevelopment followed
by an early neurological regression, with a progressive loss
of acquired cognitive, social, and motor skills in a typical
4-stage neurological regression pattern [4, 5]. Other
known features include stereotypic hand movements,
communication dysfunction, seizures, postural hypotonia,
tremors, autonomic dysfunction, microcephaly, and
growth failure [1]. It has become apparent that there is a
spectrum of severity in RTT, as some patients may present
with atypical features, sometimes overlapping with autism
spectrum disorders [3–5]. RTT is known to be caused in
the overwhelming majority of cases by sporadic de novo
loss-of-function mutations in the X-linked methyl-CpG-
binding protein 2 (MECP2) gene [6] encoding methyl-
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CpG-binding protein 2 (MeCP2), a nuclear protein that
binds to methylated CpGs and regulates gene expression
[7, 8]. Different types of mutations within MECP2 are
known to cause RTT, including missense, nonsense, dele-
tions, and insertions [9]. It should be emphasised that
most of the proteins identified in mouse serum have
orthologs in humans and other mammals [10].
Identification of Mecp2 as the disease-causing gene led
rapidly to the development of mouse models of RTT that
recapitulate, to varying degrees, the underlying molecular
and genetic defects and symptoms of the human disease
[11]. Mouse models range from Mecp2-null mutations to
specific point mutations mimicking those observed in
humans, phenocopying several motor and cognitive features
of RTT patients [12–16]. Although mice cannot model all
aspects of the human RTT, certainly they recapitulate many
features of the disease and are generally accepted as excellent
tools to study MeCP2 function [17]. An emerging role for
inflammation in human RTT is reported [18–22]. Although
MECP2 is highly expressed in several organs and tissues
besides the central nervous system (CNS), including the
spleen [16], most of the studies focused on the CNS and little
information exists on the inflammatory status in the murine
models of the disease, with few exception regarding neuroin-
flammation processes related to microglia and macrophage
function in Mecp2-null mice [23]. Furthermore, prior
reports provide a link for MECP2-RTT to increase eryth-
rocyte sedimentation rate and enhance expression of
acute-phase response (APR) proteins and cytokine dysreg-
ulation [18–22]. APR is a complex systemic early-defense
system activated by trauma, infection, stress, neoplasia,
and inflammation [24]. Although nonspecific, it serves as
a core of the innate immune response involving physical
and molecular barriers and responses that serve to prevent
infection, clear potential pathogens, initiate inflammatory
processes, and contribute to resolution and the healing
process. APR proteins, an integral part of the APR
process, have been a focus of many applications in human
diagnostic medicine and recently have been identified in
common animal species [24]. The number of protein
changes was found to be proportional to the severity of
the mutation. Our findings revealed for the first time the
presence of a subclinical chronic inflammatory status related
to the severity carried by the MECP2 gene mutation. There-
fore, inflammation seems to be a previously unrecognized
feature in RTT, which could play a role in the evolution of
the pathology and its severity. Although the genetic mecha-
nisms of RTT have been explored to an extraordinary extent,
to date, the details of the biological mechanisms linking the
MECP2 gene mutation to protein expression as a function
of clinical phenotype are yet to be clarified.
2-DE/MALDI-ToF/ToF is extremely helpful in order to
understand global protein landscape changes in a given
biological fluids and/or tissues for a given condition and is
considered to be the “gold standard” technique for identify-
ing and characterizing proteins when fitting a series of differ-
ent parameters, such as peptide matches, sequence coverage
(%), MOWSE score, and pI/Mr (kDa) [25]. In particular,
with the single exception of two proteomic studies on mouse
models [26, 27], very little information exists on possible
Mecp2 mouse model-related proteome changes. In the
present study, a validated mouse model of RTT was used,
that is, the Mecp2-308 mutated model. This model bears a
truncating mutation, leading to the expression of a protein
truncated at amino acid 308 [16, 28]. Several lines of evidence
suggest that the truncated Mecp2 protein retains at least
some of its functions (i.e., its ability to regulate BDNF gene
expression, a Mecp2 target gene) [29], thus contributing to
the milder neurobehavioral phenotype of those mice. Based
on the previous data demonstrating a clear phenotype in
Mecp2-308 females [30], the present study was carried out
in symptomatic heterozygous female mice, the genetic and
hormonal milieus that, from a translational point of view, is
closer to the ones of RTT patients; indeed, among RTT
patients, MECP2 mutations are missense and truncated
mutations, not deletions [2, 11].
The aim of the present study was to investigate in plasma
the occurrence of an inflammatory status in the experimental
Mecp2-308 mutated Rett female mouse model by using a pro-
teomic 2-DE/MALDI-ToF/ToF approach.
2. Materials and Methods
2.1. Animals. The experimental subjects were 10–12-month-
old Mecp2-308 heterozygous (Het) female mice [B6.129S-
MeCP2tm1Hzo/J, stock number: 005439] and wild-type
littermates. Mice were housed in polycarbonate transparent
cages (33× 13× 14 cm) with sawdust bedding and kept on a
12 h light-dark schedule (lights off at 8:00). Temperature
was maintained at 21± 1°C and relative humidity at 60
± 10%. Animals were provided ad libitum with a complete
pellet diet (Altromin, Germany). All procedures were carried
out in accordance with the European Communities Council
Directive (10/63/EU) and formally approved by the Italian
Ministry of Health.
2.2. Blood Sampling. Blood samples were centrifuged at 2400g
for 15min at 4°C and plasma was collected. All the manipu-
lations were carried out within 2 h after sample collection.
2.3. Electrophoretic Separation of Plasma Proteins after
Albumin and IgG Depletion. Albumin and IgG were removed
using the ProteoPrep Immunoaffinity Albumin & IgG Deple-
tion Kit (Sigma-Aldrich), and two-dimensional gel electro-
phoresis (2-DE) was performed according to Görg et al.
[31]. Samples containing 60μg of protein as determined by
Bradford [32] were denatured with 10ml of a solution
containing 10% of SDS and 2.3% of dithiothreitol (DTT).
Afterwards, samples were combined with 350ml of solubiliz-
ing buffer containing 8M urea, 2% of 3-[(3-cholamidopro-
pyl)-dimethylammonium]-1-propane sulfonate, 0.3% DTT,
and 2% of immobilized pH gradient (IPG) buffer, loaded into
18 cm IPG strips (pH3–10) nonlinear on an Ettan IPGphor
Apparatus system (GE Healthcare), and rehydrated for 7 h.
IEF was carried out for a total of 32 kVh. After focusing, the
strips were equilibrated with the buffer containing 50mM
Tris-HCl (pH8.8), 6M urea, 2% w/v SDS, 30% v/v glycerol,
and 1% w/v DTT for 15min. Subsequently, strips were
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equilibrated again with the same equilibration buffer
described above, except that it contained 4% w/v iodoaceta-
mide instead of DTT and a trace of bromophenol blue. IPG
strips and a molecular weight standard were embedded at
the top of a 1.5mm thick vertical polyacrylamide gradient
gel (8–16% T) using 0.5% w/v agarose and run at a constant
current of 40mA/gel at 20°C. The second dimension was per-
formed on an Ettan Daltsix Electrophoresis system (GE
Healthcare). Each sample was carried out in triplicate under
the same conditions.
2.4. Protein Identification. After mass spectrometry-
compatible silver staining, the preparative gel was matched
to the master gel in the analytical gel match set [33]. A
spot-picking list was generated and exported to Ettan Spot
Picker (GE Healthcare). The spots were excised and delivered
into 96-well microplates where they were destained and
dehydrated with acetonitrile (ACN) for subsequent rehydra-
tion with trypsin solution. Tryptic digestion was carried out
overnight at 37°C. Each protein spot digest (0.75ml) was
spotted into the MALDI instrument target and allowed to
dry. Then, 0.75ml of the instrument matrix solution (satu-
rated solution of α-cyano-4-hydroxycinnamic acid in 50%
ACN and 0.5% v/v trifluoroacetic acid) was applied to dried
samples which were dried again. Mass spectra were obtained
using an ultrafleXtreme MALDI-ToF/ToF (Bruker Corpora-
tion, Billerica, MA, USA), as previously described [34]. After
tryptic peptide mass acquisition, mass fingerprint searching
was carried out in Swiss-Prot/TREMBL and NCBInr data-
bases using MASCOT (Matrix Science, London, UK, http://
www.matrixscience.com). A mass tolerance of 100 ppm was
allowed and only one missed cleavage site was accepted.
Alkylation of cysteine by carbamidomethylation was
assumed as a fixed modification, whereas oxidation of methi-
onine was considered a possible modification. Criteria used
to accept identifications included the extent of sequence cov-
erage, number of matched peptides, and probabilistic scores.
Tryptic digests that did not produce MALDI-TOF unambig-
uous identifications were subjected to ESI-TRAP MS/MS
peptide sequencing on a nanospray/LCQ Deca ion trap mass
spectrometer (Thermo Finnigan, San Jose, CA, USA).
2.5. Image and Data Analysis. Gel imaging was performed by
using ImageMaster 2D Platinum v7.0 software (GE Health-
care). A reference gel for each group was defined for the
comparative analyses. The background was subtracted from
all gels using the average on-boundary method. Spot volume
was expressed as a ratio of the percentage volume (%V)
detected from the entire gel to minimize differences between
samples (i.e., normalization). Unmatched spots or spots with
significantly different %V were considered differently
expressed. Data were expressed as mean± SD/SEM or
medians [95% CI for median] as appropriate. Statistical
analysis of protein variations was performed using multiple
t-test with a false discovery rate (q) of 0.05. Differences
between groups were tested using Kruskal-Wallis test or
one-way ANOVA, with Dunn’s or Holm-Sidak’s multiple-
comparisons tests for post hoc analyses. A two-tailed P value
of less than 0.05 was considered statistically significant. The
statistical software GraphPad Prism v6.01 (GraphPad
Software Inc., La Jolla, CA, USA) and MedCalc v12.1.4 soft-
ware package (MedCalc Software, Mariakerke, Belgium)
were used.
3. Results
3.1. Protein Expression Profile Differences between Mecp2-308
and Wild-Type Mouse Models. Expression changes for a total
of 10 differentially expressed proteins were identified in the
Mecp2-308 mutated model, relative to wild type, and are
shown in 2-DE maps (Figure 1). The proteins were subse-
quently identified by mass spectrometry. Protein identifica-
tion as well as peptide matches, sequence coverage, and the
probabilistic score was obtained using the MASCOT soft-
ware (Table 1). A total of 14 spots were identified as follows:
serotransferrin (TRFE spots 1 and 2), albumin (ALBU, spot 3
as a fragment), kininogen-1 (KNG1, spot 4), alpha-
fetoprotein (FETA, spot 5), mannose-binding protein C
(MBL2, spot 6), apolipoprotein A1 (APOA1, spots 7 and 8),
alpha-1-antitrypsin (A1AT, spots 9, 10, and 11), CD5
antigen-like (CD5L, spot 12), alpha-2-macroglobulin (A2M,
spot 13), and vitamin D-binding protein (VTDB, spot 14).
A two-way analysis of variance showed significant between-
subjects effects (proteins, F: 2157.84, DF: 13, P < 0 001;
mouse category (mutated versus wild type), F: 994.35, DF:
1, P < 0 001; and proteins∗mouse category, F: 866.18, DF:
13, P < 0 001).
KNG1, FETA, MBL2, A1AT, and A2M were overex-
pressed in the examined Mecp2-308 mutated mouse model
(Figures 1 and 2, Supplementary material, Supplementary
Table 1 available online at https://doi.org/10.1155/2017/
9467819). In particular, KNG1 and A2M correspond to frag-
ments (KNG1, experimental MW: 12.6 kDa; A2M, experi-
mental MW: 64.2 kDa), both considered products of the
entire proteins. Interestingly, all the identified A1AT spots
were significantly overexpressed (P < 0 001) in the Mecp2-
308 mutated mouse model.
TRFE, ALBU, and APOA1 were found to be underex-
pressed in the mutant mouse model. In particular, ALBU
was identified as a fragment (experimental MW: 22.6 kDa),
a product of the entire protein (theoretically mapped at
MW 70.7 kDa). Of note, the CD5L spot 12 was overexpressed
(P < 0 05), while the VTDB spot 14 was significantly under-
expressed (P < 0 001) in the plasma pattern of the Mecp2-
308 mutated murine model.
3.2. Biological Functions and APR Role of Differentially
Expressed Plasma Proteins in the Mecp2-308 Female Mouse
Model. Functions of differentially expressed proteins were
evaluated in greater detail specifically for mice with the use
of ExPASy, a bioinformatics resource portal operated by
the Swiss Institute of Bioinformatics (SIB) (https://www
.expasy.org/). The majority of the proteins can be catego-
rized as either positive APR reactants (i.e., KNG1, FETA,
MBL2, A1AT, and A2M) or negative APR proteins (i.e.,
TRFE, ALBU, and APOA1). KNG1, A1AT, and A2M, three
protease inhibitors, are strictly related to inflammatory
processes and coagulation mechanisms [35–37]. TRFE,
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FETA, MBL2, ALBU, APOA1, and VTDB are known to
be mainly binding and transport proteins for bioactive
molecules and/or inflammatory mediators [38–43]. CD5L
is a key regulator of inflammatory response mechanisms
and is a macrophage-secreted glycoprotein mainly
expressed in lymphoid and inflamed tissues, regulating
the tissue macrophage homeostasis [44, 45]. A summary
of the biological functions and APR role of the
differentially expressed plasma proteins in the Mecp2-308
female model is shown in Table 2.
4. Discussion
Our findings indicate for the first time the presence of a per-
sistent unresolved inflammatory status in the Mecp2-308
female mutated mouse model of RTT. The inflammatory
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Figure 1: Silver-stained 2-DE of proteins from wild-type and Mecp2-308 mutated mouse models. A total of 60μg of protein from albumin-
depleted plasma samples was subjected to the first dimension electrophoresis on IPG strips, with nonlinear pH ranging from 3 to 10
(pI, isoelectric point), followed by SDS-polyacrylamide gradient gel (8–16% T) electrophoresis. Molecular mass (MW, kDa) and pI
markers are indicated along the gels. Numbers followed by short names denote the mass spectrometry-identified protein spots listed
in Tables 1 and 2.
Table 1: Summary of proteins identified in the Mecp2-308 plasma proteome.
Spot SwissProt code Protein name Short name Theoretical pI/Mr (kDa)
Peptide
matches
Sequence
coverage (%)
MOWSE score
1 Q921I1 Serotransferrin TRFE 6.81/79.2 5/8 8 154
2 Q921I1 Serotransferrin TRFE 6.81/79.2 9/20 16 272
3 P07724 Albumin ALBU 5.75/70.7 17/38 26 483
4 O08677 Kininogen-1 KNG1 6.05/74.1 6/9 9 219
5 P02772 Alpha-fetoprotein FETA 5.47/48.7 5/8 11 148
6 P41317 Mannose-binding protein C MBL2 4.96/26.3 3/6 14 93
7 Q00623 Apolipoprotein A1 APOA1 5.64/30.5 11/35 31 280
8 Q00623 Apolipoprotein A1 APOA1 5.64/30.5 10/35 36 239
9 P07758 Alpha-1-antitrypsin A1AT 5.33/46.0 4/10 9 81
10 P07758 Alpha-1-antitrypsin A1AT 5.33/46.0 15/50 30 804
11 P07758 Alpha-1-antitrypsin A1AT 5.33/46.0 6/11 19 143
12 Q9QWK4 CD5 antigen-like CD5L 5.01/40.3 4/7 13 133
13 Q61838 Alpha-2-macroglobulin A2M 6.27/167.0 11/25 8 370
14 P21614 Vitamin D-binding protein VTDB 5.26/54.6 14/25 7 86
Spot numbers match those reported in the representative 2-DE images in Figure 1.
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protein pattern was found to be mainly characterized by an
attenuated APR, with evident similarities to that of the
human disease. The attenuated APR pattern, observed in
theMecp2-308 mutated murine model, shares some relevant
features to the protein changes in the plasma protein pattern
from RTT girls [18, 46–48]. In particular, plasma from
Mecp2-308 mutant mouse shows increased levels of the
positive APR reactant A1AT, a multifunctional protein
involved in anti-inflammatory and tissue protective prop-
erties. More broadly, A1AT plays an important role in
modulating immunity, inflammation, apoptosis, and possi-
bly cellular senescence programs [36].
Interestingly, 4 well-known positive APR reactants (i.e.,
KNG1, FETA, MBL2, and A2M), not previously evidenced
in the plasma from RTT patients, specifically characterize
theMecp2-308 inflammatory response. Apart from their typ-
ical APR function, these proteins are also involved in the
coagulation process (i.e., KNG1 and A2M) [35, 37], fatty acid
and metal binding (i.e., FETA) [39], and innate immune
defense and inflammatory modulation (i.e., MBL2) [40]. In
particular, KNG1 and A2M are two well-known protease
inhibitors. KNG1 fragments possess biological activity with
moderate to strong correlation with specific diseases (i.e.,
early progressive renal function decline with type 1 diabetes)
Table 2: Biological functions and APR role of the differentially expressed plasma proteins in the Mecp2-308 female mouse model.
Protein name Short name Biological functions (source: ExPASy) APR proteins
Serotransferrin TRFE Iron binding and transport (−)
Albumin ALBU Transport and regulation of colloidal osmotic pressure (−)
Kininogen-1 KNG1 Mediator of inflammation and coagulation and protease inhibitor (+)
Alpha-fetoprotein FETA Inflammation and fatty acid and metal binding (+)
Mannose-binding protein C MBL2 Innate immune defense and inflammation modulation (+)
Apolipoprotein A1 APOA1 Lipid transport and metabolism (−)
Alpha-1-antitrypsin A1AT Inflammation, coagulation, and protease inhibition (+)
CD5 antigen-like CD5L Regulation of mechanisms in inflammatory responses NA
Alpha-2-macroglobulin A2M Inflammation, coagulation, and protease inhibition (+)
Vitamin D-binding protein VTDB Vitamin D sterol carrier NA
APR: acute phase response; (+): positive APR proteins; (−): negative APR proteins; NA: not applicable.
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Figure 2: Expression analysis of plasma proteins from wild-type and Mecp2-308 female mutated mouse models. Expression changes of
proteins are reported as mean± SEM and are statistically significant. Numbers followed by short names refer to proteins reported in Figure 1.
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[35], while those of murine A2M increase during inflamma-
tory responses and tumor growth [37]. Likewise, FETA
shows close connections with the modulation of the proin-
flammatory response of human keratinocytes [39]. Of note,
MBL2 comprises a cysteine-rich domain at the N-terminus
followed by a collagen-like domain, a neck region, and a car-
bohydrate recognition domain at the C-terminus [40]. This
domain recognizes and binds to chemical patterns, which
include D-mannose, L-fucose, and GlcNAc, carbohydrate
residues found on the surface of many pathogens. Further-
more, its structural features suggest a possible role in
opsonisation, activating a complement through the lectin
complement pathway [40].
A key novel finding for the Mecp2-308 plasma protein
pattern is represented by the increase in CD5L coupled with
the decrease in VTDB. These two proteins, although not
strictly APR reactants, are closely related to inflammatory
processes [43–45].
CD5L expression appears to be increased in activated
macrophages thus regulating inflammatory response pro-
cesses [49, 44, 45]. In particular, CD5L is known to prevent
Toll-like receptor-induced TNF-α and IL-1β secretion, with
a concomitant increase in IL-10 levels, thereby downregulat-
ing the tissue macrophage inflammatory reaction [45]. An
increased CD5L expression was recently evidenced in plasma
from RTT girls in the presence of an inflammatory APR pro-
tein response [48]. CD5L induction or upregulation were also
reported in response to inflammatory stimuli depending on
the variety of physiological situations [49, 50]. However, the
basic mechanism of the CD5L expression induction could
depend on a microenvironment (i.e., cell-cell interaction
between a specific type of cells and macrophages) [49].
Therefore, also cytokines produced by lymphocytes could
contribute to the upregulation of CD5L expression [49].
Interestingly, circulating levels of several cytokines including
macrophage-related cytokines such as TNF-α, IL-6, IL-
12p70, IL-10, TGF-β1, IL-8, and RANTES were found to be
abnormal in RTT girls [22]. In particular, a strongly
increased release of IL-10 was evidenced [22]. The evidenced
positive correlation between CD5L and IL-10 suggests a gen-
eral hyperactivity of the macrophage component of RTT
[48]. Several of the observed cytokine pattern changes in
MECP2-RTT girls [22] appear to reflect a likely macrophage
dysregulation/dysfunction as previously suggested for
Mecp2-null mice [19], demonstrating that MeCP2 acts as a
regulator of the response to inflammatory stimuli in the
microglia and macrophages. Further study will precisely
clarify the elements required for CD5L expression induction
in RTT. Of note, VTDB levels are reported to be decreased in
acute inflammatory conditions [43]. Moreover, VTDB
impacts on 25-hydroxyvitamin D levels under different phys-
iologic and pathologic conditions [43]. Furthermore, three
negative reactants (i.e., TRFE, ALBU, and APOA1) signifi-
cantly changed in their expression, in line with our prior
study [18]. Alterations in the TRFE levels may lead to abnor-
mal iron metabolism in RTT [38]. Expression of TRFE, pre-
viously reported to be involved in autism pathophysiology,
decreases during inflammation [38]. Thus, the observed
underexpression of TRFE in RTT, as well as in the Mecp2-
308 mutant murine model, would suggest once again that
an inflammatory process could play a key role in the patho-
genesis of the disease. ALBU is involved in the regulation of
the osmotic blood pressure, ions, hormones, and fatty acid
binding [41]. Finally, APOA1, a principal component of
high-density lipoproteins, shows an impressive portfolio of
anti-inflammatory mechanisms at the interface of vascular
inflammation and inflamed tissue [42]. Its list of properties
includes inhibition of endothelial cell adhesion molecule
expression, myeloid lineage cell proliferation, and expression
of chemokine receptors and cytokines in synovial lining cells,
and neutrophils ingress into inflamed tissues [42].
Very little is known on inflammation and the APR pro-
cess in Mep2-308 mutated mouse model, as well as in other
experimental mice. In Mecp2-308 male mouse brains, an
abnormal profile of cytokines has been observed (i.e., IL-6
was dramatically overexpressed, while TNF-α was downreg-
ulated), thus suggesting that the morphological deficits of
astrocytes are accompanied by aberrant functionality. On
the other hand, no data are available on plasma cytokine
levels in this Mecp2 mouse line. Recently, high levels of
TNF-α, IL-6, and IL-3 have been reported in an in vitro
human peripheral blood mononuclear cell (PBMC) experi-
mental setting in which the MECP2 gene was silenced [21].
Clinical studies support the presence of differences in the
clinical manifestation of the syndrome in RTT patients carry-
ing different mutations in the MECP2 gene. From a transla-
tional point of view, this is consistent with the profound
differences in the symptom gravity and in the age of their
onset exhibited by the various mouse models developed.
Indeed, different RTT models are characterized by different
genetic mutations and by consequent different degrees of
protein integrity [17]. We have chosen to study the Mecp2-
308 RTT mouse model since among RTT patients, MECP2
mutations are missense and truncated mutations, so this
model more closely resembles the clinical phenotype
shown by the majority of the patients compared to null
models. In particular, the Mecp2-308 model is character-
ized by a delayed onset of symptoms and a prolonged
life-span [16, 28] in comparison with models in which
the gene is deleted. Importantly, the behavioral phenotype
of Mecp2-308 recapitulates most of the clinical phenotype
shown by RTT patients carrying C-terminal deletions of
the MECP2 gene [51].
Reduction in several plasma proteins, potentially
affecting cholesterol transport and inhibiting oxidation phe-
nomena, is known to occur during inflammation. These pro-
teins include cholesterol ester transfer protein, hepatic lipase,
and apolipoproteins. It is thought that reduction in these
proteins, associated with an increase in positive APR
proteins, may change the high-density lipoprotein from
anti-inflammatory into proinflammatory particles [52].
A recent report, analyzing the response of astrocytes
during activation by proinflammatory stimulation, proposes
that the protective phenotype against iron-mediated oxida-
tive stress in cell death involves a complex change in the
expression and activity of several genes involved in the
control of the cellular redox state [53]. Therefore, it is
plausible that abnormal redox status and unrecognized
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proinflammatory stimuli would converge in RTT patients
to functionally damage the astrocytes within the CNS.
There is a mounting evidence for a persistent redox imbal-
ance in RTT [54–56]. This abnormal redox homeostasis
could be related to the wider context of an unresolved
inflammatory process whose fine mechanisms remain to
be elucidated.
Inflammation plays an important role in the patho-
physiology of several common diseases, such as Alzhei-
mer’s and atherosclerosis. Thus, the cellular mechanisms
by which resolution occurs and the key biochemical path-
ways associated with the return to homeostasis/catabasis
(return from disease) clearly open many new avenues for
potential therapeutic interventions in a wide range of
diseases associated with unresolved inflammation [57].
RTT appears to be more complex than previously
thought. A gene sequence analysis has indicated several hun-
dreds of gene mutations associated with the MECP2 gene
mutation and, therefore, to be considered potential disease
modifiers [58].
MECP2 levels start to increase postnatally with the
protein being abundant in the mature nervous system
[59]. MeCP2 protein expression is not uniform in different
neuronal cell populations and parts of the brain [60] and
is known to change with age [61]. MeCP2 is a multifunc-
tional protein influencing gene expression and metabolism
on many levels [62]. MeCP2 is currently considered a
global, genome-wide transcriptional regulator (i.e., mainly
repressor) whose function is well correlated with DNA
methylation density for a large proportion of unusually
long brain-specific genes [62]. Likely, a loss of MeCP2
function causes a transcriptional imbalance leading to a
suboptimal brain homeostasis [63]. A clear cut proof-of-
concept demonstration for the effects of MeCP2 gene
mutations on the homeostasis of the brain is the absence
of major phenotypes associated with Rett-like mice when
levels of the central nervous system MeCP2 are normal
[64]. MECP2 dampens neuronal transcription globally,
thus allowing activity-related responses essential for the
learning process and specific synapsis formation [65, 66].
Although the genetic mechanisms of RTT have been
explored to an extraordinary extent, to date the details of
the biological mechanisms linking theMECP2 gene mutation
to protein expression as a function of clinical phenotype have
yet to be clarified. The findings of the present study add a fur-
ther phenotypical feature, thus expanding our knowledge on
the molecular cascade of events that lead to the disease
phenotype.
5. Conclusion
Our results indicate for the first time the occurrence of a per-
sistent unresolved inflammation of unknown origin in the
Mecp2-308 female mouse model of RTT, which appears to
be helpful to elucidate in greater detail the importance of
the inflammatory status, disentangle the role of inflammation
in RTT on the phenotype, and contribute in developing
inflammation-targeted therapeutic strategies.
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